660P Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study.

Authors :: Mansi, L.
Ghiringhelli, F.
de la Fouchardiere, C.
You, B.
Kalbacher, E.
Bazan, F.
Fagnoni Legat, C.
Meynard, G.
Maurina, T.
Vienot, A.
Vernerey, D.
Meurisse, A.
Fumet, J-D.
Kroemer, M.
Tanang, A.
Rebucci-Peixoto, M.
Spehner, L.
Kim, S.
Adotevi, O.
Borg, C.
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS520-S520. 1p.
Publication Year :: 2024

Full Text Access

Tools